Month: March 2022

Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s diseaseDUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) — Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody in development for the treatment of Alzheimer’s disease (AD). Prothena has initiated the Phase 1 single ascending dose (SAD) study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of PRX012 in both healthy volunteers and patients with AD. Prothena expects to initiate the Phase...

US Nuclear Launching Fundraising Campaign to Send More DroneRADs to Ukraine

Written by Customer Service on March 28, 2022. Posted in Public Companies.

LOS ANGELES, March 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – US Nuclear (OTC-QB: UCLE) is launching a fundraising campaign through Fundly.com in order to send more DroneRAD radiation detection drones to Ukraine. With the conflict raging in Ukraine, there is significant concern over a nuclear disaster, either from use of nuclear weapons or as fallout from explosive damage to the local nuclear power plants or other facilities storing radioactive materials (disposal sites, hospitals, labs). US Nuclear has already announced its first DroneRAD going to Ukraine, but is seeking public help in order to raise funds to send more units. Russian troops first took over Chernobyl nuclear facility, which had its necessary power supply disconnected on March 9 due to continued fighting and damage to the electrical lines. At least 20,000 spent...

BoxScore Brands, Inc. Announces Corporate Update

Written by Customer Service on March 28, 2022. Posted in Public Companies.

LAS VEGAS, March 28, 2022 (GLOBE NEWSWIRE) — BoxScore Brands, Inc (OTC Pink Current: BOXS) (“BoxScore”, the “Company”) a U.S.-based renewable energy company focused on the extraction, refining, manufacturing, and distribution of precious technical minerals, is pleased to announce a corporate update. “On behalf of all of us at BoxScore Brands, I would like to sincerely thank our shareholders for their patience and encouragement over the past several months. We have spent a tremendous amount of time working and relationship building to ensure that our business plan and corporate structure have solid foundations for future growth, and we are very excited about the future of the company,” stated Andrew Boutsikakis, CEO of BoxScore. “As stated in our February 14thnews release, we are deeply focused on the development and advancement...

Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio (the “Praesidio Shares”) for aggregate consideration of C$4,000,000 in common shares (the “Consideration Shares”) of the Company (the “Transaction”). Upon closing of the Transaction (“Closing”), Praesidio will operate as a wholly-owned subsidiary of the Company. Praesidio Health (https://www.praesidiohealth.com/) is an industry-leading, Canadian medical research...

Dimensional Fund Advisors Ltd. : Form 8.3 – GXO LOGISTICS INC – Ordinary Shares

Written by Customer Service on March 28, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate...

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Written by Customer Service on March 28, 2022. Posted in Earnings Releases And Operating Results.

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “The past year represented a truly transformational period for Checkpoint Therapeutics, with the foundation laid for multiple significant potentially value enhancing catalysts in 2022. Following the positive topline results from our ongoing registrational trial of cosibelimab in metastatic cutaneous squamous cell carcinoma announced earlier this year, we look forward to a planned Biologics License Application submission for cosibelimab later in 2022.” Mr. Oliviero continued,...

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Dr. Seidel has more than 20 years of experience in the medical device industry BURLINGTON, Mass. and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim “Joe” Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy. Dr. Seidel has more than 20 years of experience in the medical device industry and has held positions in business development, corporate strategy, program management, and research and development. He will be responsible for pursuing strategic opportunities for BrainsWay and overseeing its global corporate development initiatives. “Joe brings a unique breadth of experience...

Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors

Written by Customer Service on March 28, 2022. Posted in Public Companies.

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 28 MARCH 2022, 3:00 P.M. EEST Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors The Annual General Meeting of Enento Group Plc was held today at the headquarters of the company in Helsinki, Finland under special arrangements due to the Covid-19 pandemic. 82 shareholders representing 17 474 412 shares and votes were represented at the meeting. The Annual General Meeting approved the Financial Statements and discharged the members of the Board of Directors and the company’s CEO from liability for the financial year 2021 and resolved to approve the Remuneration report for governing bodies. The Annual General Meeting approved the Board of Directors’ proposal to distribute funds of EUR 1.00 per share as an equity repayment from the reserve for invested unrestricted...

ME2C Environmental Exercises Right of First Refusal with Major U.S. Utility, Patented Mercury Emissions Technology Licensee, to Supply Product Valued at $1 Million Annually

Written by Customer Service on March 28, 2022. Posted in Public Companies.

ME2C to Supply Its Custom Sorbents; Increasing the Company’s Momentum Across U.S. Coal-Fired Market Corsicana, TX, March 28, 2022 (GLOBE NEWSWIRE) — Midwest Energy Emissions Corp. (OTCQB: MEEC) (“ME2C Environmental ” or the “Company”), a leading environmental technologies firm, announced today that it has exercised its right of first refusal (“ROFR”) for mercury emissions capture product supply with a significant coal-powered utility operating in the Midwest. This major utility entered into a license agreement with the Company in 2021 which agreement provided a ROFR with respect to certain future supply business. ME2C Environmental is exercising the ROFR and matching the terms of an offer made by another supplier for a direct three-year supply order and a renewal option, which is expected to have a value...

Sunrun Announces Date and Conference Call Details for First Quarter 2022 Earnings Report

Written by Customer Service on March 28, 2022. Posted in Public Companies.

Earnings Release and Conference Call Scheduled for May 4, 2022 SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN) today announced that it will issue its first quarter 2022 earnings report after the market closes on Wednesday, May 4, 2022. A conference call has been scheduled to discuss these earnings results at 1:30 p.m. Pacific Time. The conference call can be accessed live via the Sunrun Investor Relations website at https://investors.sunrun.com or over the phone by dialing (877) 407-5989 (toll-free) or (201) 689-8434 (toll). An audio replay will be available following the call on the Sunrun Investor Relations website for approximately one month. About Sunrun Sunrun Inc. (Nasdaq: RUN) is the nation’s leading home solar, battery storage, and energy services company. Founded...

Month: March 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals